Table 1 Assumed M72/AS01E and BCG-revaccination scenarios
| Â | M72/AS01E | BCG-revaccination | ||
|---|---|---|---|---|
Characteristic | Basecase | Varied in univariate | Basecase | Varied in univariate |
Policy scenarios | ||||
 Age targeting | Routine age 15, campaign for ages 16–34 | Older ages (campaign for ages 18–55) Elderly ages (routine age 60, campaign for ages 61 +) | Routine age 10, campaign for ages 11–18 | Older ages (routine age 15, campaign for ages 16–34) Elderly ages (routine age 60, campaign for ages 61 +) |
Vaccine characteristic and coverage scenarios | ||||
 Vaccine efficacy | 50% | 60% 70% | 45% | 70% |
 Duration of protection | 10 years | 5 years 15 years 20 years | 10 years | 5 years 15 years 20 years |
 Host infection status | AI | CI | NCI | AI |
 Mechanism of effect | Prevention of disease | Prevention of infection and disease | Prevention of infection | Prevention of infection and disease |
 Introduction year (years of any repeat campaigns) | 2030 (2040) | 2036 (2046) | 2025 (2035, 2045) | 2031 (2041) |
 Achieved vaccine coverage | Routine = 80%, campaign = 70% | Routine = 70%, campaign = 50% Routine = 90%, campaign = 90% | Routine and campaign = 80% | Routine and campaign = 70% Routine and campaign = 90% |